INS and type 2 diabetes mellitus: China. Patients with T2DM n = 65. Exenatide n = 19 (male/female 9/10), dulaglutide n = 19 (male/female 11/8), insulin glargine n = 10 (male/female 7/3), placebo n = 17 /male/female 9/8)